Skye Bioscience, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Skye Bioscience, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q4 2024.
  • Skye Bioscience, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $2.09M, a 252% increase year-over-year.
  • Skye Bioscience, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $8.32M, a 742% increase year-over-year.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8.32M, a 742% increase from 2023.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $988K, a 62.4% increase from 2022.
  • Skye Bioscience, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $608K, a 30% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $8.32M $2.09M +$1.5M +252% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 $6.82M $1.92M +$1.76M +1099% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $5.06M $1.83M +$1.73M +1677% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $3.33M $2.48M +$2.35M +1783% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $988K $593K +$411K +225% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 $577K $160K +$16.1K +11.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $561K $103K -$41.5K -28.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $602K $132K -$5.78K -4.21% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $608K $182K +$60.4K +49.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 $548K $144K -$345K -70.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $893K $144K +$32.7K +29.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $860K $137K -$9.22K -6.29% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $869K $122K +$60.4K +98.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $809K $489K +$341K +230% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $468K $112K +$83K +289% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $385K $147K +$82.4K +129% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $303K $61.5K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $148K -$21.7K -12.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $28.7K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $64.1K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q3 2019 $170K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q3 2017 $182K Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-14
Q2 2017 $182K Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-11
Q1 2017 $152K -$29.4K -16.2% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-12
Q1 2016 $182K +$45K +32.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
Q3 2015 $4.29K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $123K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-12
Q1 2015 $137K +$137K Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-13
Q1 2014 $0 Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.